Neuren Pharma (NEU) is held by 24 ASX ETFs. Over all time it rose 2.7%: on $10,000, +$266. We explain 4 big moves in that time.
About NEU
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.6b
- Held by24 ETFs
- Big moves4 in all time
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +16.9%5 Aug 2026· Sector Flow
NEU.AX rose sharply alongside a broad lift in Australian healthcare sector stocks, likely driven by positive sector-wide sentiment or macro tailwinds benefiting health equities that day.
- +36.1%29 Jun 2026· Regulatory
European regulator CHMP backed approval of Neuren's flagship drug Daybue, triggering a US$35m milestone payment and sending the stock up 35-36%.
- +21.1%14 Apr 2025· Unknown
Investors likely bought NEU shares after an AFR article highlighted a heart device maker, celebrated as 'could be next Cochlear or ResMed', which won FDA approval — a positive sector or peer signal for pharmaceutical companies.
- +15.1%8 Nov 2024· Unknown
No news articles were found to explain the 15.07% price increase; the cause is unknown.
Held by 24 ETFs
Of every $10,000 in each fund, how much is in NEU today.
- SMLLBetaShares Australian Small Companies Select ETF$2152.15%
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$880.88%
- ISOiShares S&P/ASX Small Ordinaries ETF$870.87%
- QHSMVanEck MSCI International Small Companies Quality (AUD Hedged) ETF$600.60%
- QSMLVanEck MSCI International Small Companies Quality ETF$580.58%
- FAIRBetaShares Australian Sustainability Leaders ETF$480.48%
- ROYLBetaShares Global Royalties ETF$470.47%
- GRPAGlobal X S&P Australia GARP ETF$420.42%
- VSOVanguard MSCI Australian Small Companies Index ETF$380.38%
- AECVBETASHARES AUSTRALIAN SHARES CATHOLIC VALUES ETF$320.32%
Why did NEU rise 21.1% on 14 Apr 2025?
Neuren Pharma
Investors likely bought NEU shares after an AFR article highlighted a heart device maker, celebrated as 'could be next Cochlear or ResMed', which won FDA approval — a positive sector or peer signal for pharmaceutical companies.
The only news article around the date discusses a different heart device maker's FDA approval and its potential to become a major medical company, with no explicit mention of Neuren Pharmaceuticals. While this could reflect positive sector sentiment, there is no direct link to NEU's price move. The move could also be driven by an unannounced corporate event, so confidence is limited.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
Evidence
News coverage
What it did to the 24 ETFs holding NEU
On $10,000 in each fund, at the weight it holds today
- SMLL2.15% of the fund+$45
- SSO0.88% of the fund+$19
- ISO0.87% of the fund+$18
- QHSM0.60% of the fund+$13
- QSML0.58% of the fund+$12
- FAIR0.48% of the fund+$10
- ROYL0.47% of the fund+$10
- GRPA0.42% of the fund+$9
- VSO0.38% of the fund+$8
- AECV0.32% of the fund+$7
The 10 that hold it most. All 24 are listed on the page under Held by.